Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia

Current Opinion in Investigational Drugs

Volumn 11, Issue 12, 2010, Pages 1450-1465

  Santos, Fabio P S ^a   Kantarjian, Hagop ^b   Cortes, Jorge ^b   Quintas Cardama, Alfonso ^b  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BAFETINIB; BCR ABL PROTEIN; BOSUTINIB; CASPASE 3; CASPASE 8; CASPASE 9; DASATINIB; IMATINIB; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NILOTINIB;

ACUTE KIDNEY FAILURE; AREA UNDER THE CURVE; ARTICLE; B CELL LEUKEMIA; BRAIN METASTASIS; BRAIN TUMOR; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; GLIOMA; HUMAN; HYPERTENSION; HYPERURICEMIA; IN VITRO STUDY; INTRAHEPATIC CHOLESTASIS; LYMPHATIC LEUKEMIA; MAXIMUM PLASMA CONCENTRATION; MUTATION; NONHUMAN; PERICARDIAL EFFUSION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG EVALUATION, PRECLINICAL; HUMANS; LEUKEMIA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79952743082     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (121)

1. Phenylamino-pyrimidine (PAP)-Derivatives: A new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors. Zimmermann J, Buchdunger E, Mett H, Meyer T, Lydon NB, Traxler P BIOORG MED CHEM LETT 1996 6 11 1221-1226
2. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J SCIENCE 2000 289 5486 1938-1942
3. Chronic myeloid leukemia. Sawyers CL N ENGL J MED 1999 340 17 1330-1340 (Pubitemid 29196596)
4. Distribution of STI-571 to the brain is limited by P-glycoprotein- mediated effux. Dai HQ, Marbach P, Lemaire M, Hayes M, Elmquist WF J PHARMACOL EXP THER 2003 304 3 1085-1092 (Pubitemid 36254421)
5. CNS-9, a novel specifc inhibitor of Abl tyrosine kinase overcomes resistance mechanism of imatinib. Kimura S, Segawa H, Kuroda J, Yuasa T, Maekawa T, Nakahata T BLOOD 2004 104 11 Abs 761
6. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA et al N ENGL J MED 2004 351 15 1502-1512 (Pubitemid 39315317)
7. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K, Yokota A, Kamitsuji Y, Kawata E, Ashihara E, Nakaya Y et al BLOOD 2005 106 12 3948-3954 (Pubitemid 41739036)
8. Simultaneous targeting of Lyn and Bcr-Abl kinases by NS-187 cures mice bearing imatinib-resistant leukemic cells. Naito H, Kimura S, Nakaya Y, Naruoka H, Wakayama T, Kimura S, Ito S, Ashihara E, Maekawa T, Hirabayashi K BLOOD 2005 106 11 Abs 1518
9. A dual Bcr-Abl/Lyn tyrosine kinase inhibitor, NS-187, is a novel agent for imatinib-resistant leukemia. Kimura S, Naito H, Y okota A, Kamitsuji Y, Kawata E, Ashihara E, Nakaya Y, Naruoka H, Wakayama T, Asaki T, Niwa T et al BLOOD 2005 106 11 Abs 1522
10. Anti-tumor activity of a novel Bcr-Abl/Lyn dual inhibitor, NS-187, in murine CNS Ph+ leukemia models. Yokota A, Kimura S, Oyama T, Ashihara E, Naito H, Urasaki Y, Ueda T, Terui U, Hatake K, Hirabayashi K, Maekawa T BLOOD 2005 106 11 Abs 493
11. INNOVIVE Pharmaceuticals licenses potent dual Bcr-Abl/Lyn kinase inhibitor; initial development target is chronic myelogenous leukemia. Innovive Pharmaceuticals Inc PRESS RELEASE 2006 January 05
12. Tyrosine kinases as targets for cancer therapy. Krause DS, Van Etten RA N ENGL J MED 2005 353 2 172-187 (Pubitemid 41058349)
13. NS-187, a novel Bcr-Abl inhibitor, induces cell death more potent and rapid than imatinib mesylate in Bcr-Abl-positive cell lines. Kamitsuji Y, Adachi S, Watanabe M, Matsubara H, Mizushima Y, Hiraumi Y, Watanabe KI, Ashihara E, Kimura S, Maekawa T, Nakahata T PROC AM ASSOC CANCER RES 2006 47 Abs 5473
14. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. O'Hare T, Walters DK, Stoffregen EP, Jia TP, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MWN, Druker BJ CANCER RES 2005 65 11 4500-4505 (Pubitemid 40740783)
15. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL et al CANCER CELL (ONLINE) 2005 7 2 129-141 (Pubitemid 40248339)
16. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K et al N ENGL J MED 2006 354 24 2542-2551 (Pubitemid 43882350)
17. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA et al N ENGL J MED 2006 354 24 2531-2541 (Pubitemid 43882349)
18. Cyclosporin A, a P-gp inhibitor, augments the anti-central nervous system Ph+ leukemia effects of INNO-406. Yokota A, Kimura S, Masuda S, Ashihara E, Urasaki Y, Terui Y, Ruthardt M, Ueda T, Hatake K, Inui K, Maekawa T BLOOD 2006 108 11 Abs 834
19. Cell death mechanisms induced by INNO-406, a novel tyrosine kinase inhibitor for imatinib-resistant Ph+ leukemia. Kamitsuji Y, Adachi S, Watanabe M, Matsubara H, Mizushima Y, Hiraumi Y, Watanabe K-I, Tanaka H, Kuroda J, Ashihara E, Kimura S et al BLOOD 2006 108 11 Abs 2177
20. BH3 mimetic augments the induction of apoptosis by INNO-406, a novel Bcr-Abl/Lyn inhibitor, in Bcr-Abl+ leukemic cells. Kuroda J, Kimura S, Strasser A, Andreeff M, Ashihara E, Tabe, Taniwaki M, Maekawa T BLOOD 2006 108 11 Abs 2178
21. The ATP competitor INNO-406 (NS-187) inhibits proliferation and survival of mouse cells expressing several immatinib mesylate resistant Bcr/Abl mutants and cells from CML patients. Tao W, Sun T, Craig AR, Cortes JE, Ottmann OG, Hochhaus A, Reddy PE, Kantarjian HM, Arlinghaus RB BLOOD 2006 108 11 Abs 2179
22. INNOVIVE Pharmaceuticals announces receipt of FDA orphan drug designation for INNO-406 for the treatment of chronic myelogenous leukemia. Innovive Pharmaceuticals Inc PRESS RELEASE 2007 January 04
23. INNO-406, a novel Bcr-Abl/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph(+) leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Yokota A, Kimura S, Masuda S, Ashihara E, Kuroda J, Sato K, Kamitsuji Y, Kawata E, Deguchi Y, Urasaki Y, Terui Y et al BLOOD 2007 109 1 306-314 (Pubitemid 46053071)
24. Cell death and autophagy induced by INNO-406, a novel Bcr-Abl inhibitor, in Philadelphia leukemias. Kamitsuji Y, Adachi S, Kimura S, Watanabe K, Watanabe M, Matsubara H, Mizushima Y, Hiraumi Y, Yui Y, Kuroda J, Ashihara E et al AM ASSOC CANCER RES ANN MEET 2007 98 April 16 Abs 2768
25. A phase I study of INNO-406, a dual inhibitor of Abl/Lyn kinases, in adult patients with imatinib-resistant or intolerant Philadelphia chromosome positive (Ph+) leukemias. Kantarjian HM, Cortes JE, Craig AR, O'Brien S, Jones D, Hochhaus A, Raupach-Rosin H, Rios M-B, Zander C, Gleich LL, Carroll EP et al AM ASSOC CANCER RES ANN MEET 2007 98 April 16 Abs 2637
26. A phase I study of INNO-406, a dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib. Craig AR, Kantarjian HM, Cortes JE, Jones D, Hochhaus A, O'Brien S, Rios M, Zander C, Gleich L, Carroll EP, Ottmann OG AM SOC CLIN ONCOL 2007 43 June 02 Abs 7046
27. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL BLOOD 2007 109 9 4016-4019 (Pubitemid 46641755)
28. The natural history of fudarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Tam CS, O'Brien S, Lerner S, Khouri I, Ferrajoli A, Faderl S, Browning M, Tsimberidou AM, Kantarjian H, Wierda WG LEUK LYMPHOMA 2007 48 10 1931-1939 (Pubitemid 47542979)
29. Flying under the radar: The new wave of Bcr-Abl inhibitors. Quintas-Cardama A, Kantarjian H, Cortes J NAT REV DRUG DISCOV 2007 6 10 834-848 (Pubitemid 47500507)
30. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant Cell Lines. Kimura S, Deguchi Y, Ashihara E, Niwa T, Hodohara K, Fujiyama Y, Maekawa T AM SOC HEMATOL ANN MEET EXPOSITION 2007 49 December 10 Abs 2952
31. Anti-tumor effect of INNO-406, a novel Bcr-Abl inhibitor in combination with cyclosporin A against the murine central nervous system and systemic leukemia model. Yokota A, Kimura S, Masuda S, Ashihara E, Urasaki Y, Terui Y, Ruthardt M, Ueda T Hatake K, Inui KI, Maekawa T AM SOC HEMATOL ANN MEET EXPOSITION 2007 49 December 8 Abs 1598
32. A phase I study of INNO-406 in patients with advanced philadelphia (Ph+) chromosome-positive leukemias who are resistant or intolerant to imatinib and second generation tyrosine kinase inhibitors. Kantarjian HM, Cortes J, Le Coutre P, Nagler A, Pinilla J, Hochhaus A, Jones D, Craig AR, Carroll E, Ottmann OG AM SOC HEMATOL ANN MEET EXPOSITION 2007 49 December 10 Abs 469
33. The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias. Kamitsuji Y, Kuroda J, Kimura S, Watanabe KI, Ashihara E, Yui Y, Watanabe M, Matsubara H, Mizushima Y, Hiraumi Y, Tanaka H et al AM SOC HEMATOL ANN MEET EXPOSITION 2007 49 December 10 Abs 2951
34. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J et al N ENGL J MED 2005 352 10 987-996 (Pubitemid 40349501)
35. Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is active in patients with imatinib-resistant or-intolerant accelerated-phase chronic myelogenous leukemia. le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG, Kuliczkowski K et al BLOOD 2008 111 4 1834-1839 (Pubitemid 351451490)
36. Early results of a chemoimmunotherapy regimen of fudarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C et al J CLIN ONCOL 2005 23 18 4079-4088 (Pubitemid 46211313)
37. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant Bcr-Abl mutations including T315I. Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E, Benten D, Bokemeyer C, Fiedler W, Moll J, Brummendorf TH BLOOD 2008 111 8 4355-4364
38. Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with Bcr-Abl gene amplifcation. Morinaga K, Yamauchi T, Kimura S, Maekawa T, Ueda T INT J CANCER 2008 122 11 2621-2627 (Pubitemid 351590500)
39. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Deguchi Y, Kimura S, Ashihara E, Niwa T, Hodohara K, Fujiyama Y, Maekawa T LEUK RES 2008 32 6 980-983
40. A phase I study of INNO-406 in patients with advanced Philadelphia chromosome-positive (Ph+) leukemias who are resistant or intolerant to imatinib and may have also failed second-generation tyrosine kinase inhibitors. Pinilla-Ibarz J, Kantarjian HM, Cortes JE, le Coutre P, Nagler A, Hochhaus A, Jones D, Kimura S, Giampalmi J, Gleich L, Ottmann OG AM SOC CLIN ONCOL ANN MEET 2008 44 May 29 Abs 7018
41. CytRx Corporation completes acquisition of Innovive Pharmaceuticals, Inc. CytRx Corp PRESS RELEASE 2008 September 22
42. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ BLOOD 2008 111 12 5446-5456
43. AP24534, a pan-Bcr-Abl inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. O'Hare T, Shakespeare WC, Zhu XT, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou TJ, Huang WS, Xu QH, Metcalf CA et al CANCER CELL (ONLINE) 2009 16 5 401-412
44. CytRx announces 2010 clinical and development milestones. CytRx Corp PRESS RELEASE 2010 January 21
45. A comprehensive target selectivity survey of the Bcr-Abl kinase inhibitor INNO-406 by kinase profling and chemical proteomics in chronic myeloid leukemia cells. Rix U, Rix LLR, Terker AS, Fernbach NV, Hantschel O, Planyavsky M, Breitwieser FP, Herrmann H, Colinge J, Bennett KL, Augustin M et al LEUKEMIA 2010 24 1 44-50
46. Committee for Orphan Medicinal Products (COMP) 2-3 February 2010. European Medicines Agency PRESS RELEASE 2010 February 03
47. CytRx to receive $3.8 million from sale of RXi Pharmaceuticals common stock. CytRx Corp PRESS RELEASE 2010 March 23
48. CytRx's Bafetinib receives positive opinion from the committee for Orphan Medicinal Products in the European Union for treatment of CML. CytRx Corp PRESS RELEASE 2010 April 20
49. CytRx initiates phase 2 clinical trial with bafetinib in B-cell chronic lymphocytic leukemia. CytRx Corp PRESS RELEASE 2010 May 28
50. Preclinical evaluation of bafetinib for treatment of glioblastoma multiforme. Velcheti V, Peterson B, Levitt D, Prakash O AM SOC CLIN ONCOL ANN MEET 2010 46 June 6 Abs 2082
51. Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Kantarjian H, le Coutre P, Cortes J, Pinilla-Ibarz J, Nagler A, Hochhaus A, Kimura S, Ottmann O CANCER 2010 116 11 2665-2672
52. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen ZX, Mayer J, Pasquini R, Nakamae H et al N ENGL J MED 2010 362 24 2260-2270
53. FDA approves new indication for Tasigna. The Food and Drug Administration PRESS RELEASE 2010 June 17
54. FDA approves Tasigna for newly diagnosed chronic myeloid leukemia patients, data demonstrate major advance over Gleevec. Novartis AG PRESS RELEASE 2010 June 17
55. In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring abl kinase domain mutations. Naito H, Kimura S, Nakaya Y, Naruoka H, Kimura S, Ito S, Wakayama T, Maekawa T, Hirabayashi K LEUK RES 2006 30 11 1443-1446 (Pubitemid 44307316)
56. Effect of tyrosine kinase inhibitor INNO-406 on human mast cells bearing mutated c-Kit tyrosine kinase. Pan JX, Kantarjian H, Cortes J, Giles F, Verstovsek S BLOOD 2006 108 11 Abs 4890
57. Development of NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor. Kimura S, Niwa T, Hirabayashi K, Maekawa T CANCER CHEMOTHER PHARMACOL 2006 58 S55-S61
58. Sensitivity of human cells bearing oncogenic mutant Kit isoforms to the novel tyrosine kinase inhibitor INNO-406. Pan J, Quintas-Cardama A, Manshouri T, Cortes J, Kantarjian H, Verstovsek S CANCER SCI 2007 98 8 1223-1225 (Pubitemid 46993542)
59. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Kuroda J, Kimura S, Strasser A, Andreeff M, O'Reilly LA, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R et al CELL DEATH DIFFER 2007 14 9 1667-1677 (Pubitemid 47278852)
60. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, allagher N et al N ENGL J MED 2010 362 24 2251-2259
61. The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias. Kamitsuji Y, Kuroda J, Kimura S, Toyokuni S, Watanabe K, Ashihara E, Tanaka H, Yui Y, Watanabe M, Matsubara H, Mizushima Y et al CELL DEATH DIFFER 2008 15 11 1712-1722
62. Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives. Horio T, Hamasaki T, Inoue T, Wakayama T, Itou S, Naito H, Asaki T, Hayase H, Niwa T BIOORG MED CHEM LETT 2007 17 10 2712-2717 (Pubitemid 46636265)
63. The dual Abl/Src inhibitors dasatinib, SKI-606, and INNO-406 are potent inhibitors of T-cell acute lymphoblastic leukemia cell lines expressing the NUP214-Abl1 fusion kinase. Quintis-Cardama A, Manshouri T, Tong W, Kantarjian H, Cortes J, Garcia-Manero G PROC AM ASSOC CANCER RES 2007 48 Abs 1825
64. Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib, and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with bcr-abl gene amplifcation. Morinaga K, Yamauchi T, Kimura S, Maekawa T, Ueda T PROC AM ASSOC CANCER RES 2007 48 Abs 3246
65. Timeline-The discovery of receptor tyrosine kinases: Targets for cancer therapy. Gschwind A, Fischer OM, Ullrich A NAT REV CANCER 2004 4 5 361-370 (Pubitemid 38579482)
66. Key cancer cell signal transduction pathways as therapeutic targets. Bianco RB, Melisi D, Ciardiello F, Tortora G EUR J CANCER 2006 42 3 290-294 (Pubitemid 43132883)
67. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EWT, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F et al BIOCHIM BIOPHYS ACTA MOL CELL RES 2007 1773 8 1263-1284 (Pubitemid 47125967)
68. Translation of the Philadelphia chromosome into therapy for CML. Druker BJ BLOOD 2008 112 13 4808-4817
69. Molecular biology of Bcr-Abl1-positive chronic myeloid leukemia. Quintas-Cardama A, Cortes J BLOOD 2009 113 8 1619-1630
70. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Deininger M, O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, Radich JP, Hatfeld AK, Mone M, Filian J, Reynolds J et al BLOOD 2009 114 22 Abs 1126
71. Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Apperley JF LANCET ONCOL 2007 8 11 1018-1029 (Pubitemid 47629897)
72. Bcr-Abl independence and Lyn kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M BLOOD 2003 101 2 690-698 (Pubitemid 36077594)
73. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, Bcr-Abl1(+) leukemia cells. Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM NAT MED 2004 10 11 1187-1189 (Pubitemid 39540433)
74. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. Dai Y, Rahmani M, Corey SJ, Dent P, Grant S J BIOL CHEM 2004 279 33 34227-34239 (Pubitemid 39318046)
75. Src family kinase activity is up-regulated in hormone-refractory prostate cancer. Tatarov O, Mitchell TJ, Seywright M, Leung HY, Brunton VG, Edwards J CLIN CANCER RES 2009 15 10 3540-3549
76. Lyn kinase activity is the predominant cellular Src kinase activity in glioblastoma tumor cells. Stettner MR, Wang W, Nabors LB, Bharara S, Flynn DC, Grammer JR, Gillespie GY, Gladson CL CANCER RES 2005 65 13 5535-5543 (Pubitemid 40911153)
77. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. Contri A, Brunati AM, Trentin L, Cabrelle A, Miorin M, Cesaro L, Pinna LA, Zambello R, Semenzato G, Donella-Deana A J CLIN INVEST 2005 115 2 369-378 (Pubitemid 40385478)
78. Identifcation of a novel TEL-Lyn fusion gene in primary myelofbrosis. Tanaka H, Takeuchi M, Takeda Y, Sakai S, Abe D, Ohwada C, Sakaida E, Shimizu N, Saito Y, Miyagi S, Iwama A et al LEUKEMIA 2010 24 1 197-200
79. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LAM, Das J, Doweyko AM, Fairchild C et al J MED CHEM 2004 47 27 6658-6661 (Pubitemid 40053752)
80. Effcacy and safety of dasatinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia in blast phase. Cortes J, Kim DW, Raffoux E, Martinelli G, Ritchie E, Roy L, Coutre S, Corm S, Hamerschlak N, Tang JL, Hochhaus A et al LEUKEMIA 2008 22 12 2176-2183
81. Dasatinib induces signifcant hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in accelerated phase. Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, Amadori S, de Souza CA, Lipton JH, Hochhaus A, Heim D et al BLOOD 2007 109 10 4143-4150 (Pubitemid 46743375)
82. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D et al LEUKEMIA 2008 22 6 1200-1206 (Pubitemid 351833788)
83. Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R et al BLOOD 2007 110 10 3540-3546 (Pubitemid 350159618)
84. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J CANCER RES 2002 62 15 4236-4243 (Pubitemid 34827278)
85. NS-187 (INNO-406), a Bcr-Abl1/Lyn dual tyrosine kinase inhibitor. Niwa T, Asaki T, Kimura S ANAL CHEM INSIGHTS 2007 2 93-106
86. Hydrogen bond structural group constants. Abraham MH, Platts JA J ORG CHEM 2001 66 10 3484-3491 (Pubitemid 32878957)
87. Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl infuences the sensitivity towards imatinib in vivo. Miething C, Mugler C, Grundler R, Hoepf J, Bai RY, Peschel C, Duyster J LEUKEMIA 2003 17 9 1695-1699 (Pubitemid 37185242)
88. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leis JF, Stepan DE, Curtin PT, Ford JM, Peng B, Schubach S, Druker BJ, Maziarz RT LEUK LYMPHOMA 2004 45 4 695-698 (Pubitemid 38256028)
89. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Pfeifer H, Wassmann B, Hofmann WK, Komor M, Scheuring U, Bruck P, Binckebanck A, Schleyer E, Gokbuget N, Wolff T, Lubbert M et al CLIN CANCER RES 2003 9 13 4674-4681 (Pubitemid 37336441)
90. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvalo PP, Kitada S, Deng XM, Zhai DY, Shi YX, Sneed T, Verhaegen M et al CANCER CELL (ONLINE) 2006 10 5 375-388 (Pubitemid 44693472)
91. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: Long-term follow-up. Garg RJ, Kantarjian H, O'Brien S, Quintas-Cardama A, Faderl S, Estrov Z, Cortes J BLOOD 2009 114 20 4361-4368
92. Pleural effusions in patients with chronic myeloid leukemia treated with dasatinib may have an immune-mediated pathogenesis. de Lavallade H, Punnialingam S, Milojkovic D, Bua M, Khorashad JS, Gabriel IH, Chaidos A, Olavarria E, Goldman JM, Apperley JF, Marin D BR J HAEMATOL 2008 141 5 745-747 (Pubitemid 351667633)
93. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Quintas-Cardama A, Kantarjian H, Ravandi F, O'Brien S, Thomas D, Vidal-Senmache G, Wierda W, Kornblau S, Cortes J CANCER 2009 115 11 2482-2490
94. The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Gratacap MP, Martin V, Valera MC, Allart S, Garcia C, Sie P, Recher C, Payrastre B BLOOD 2009 114 9 1884-1892
95. Cancer facts & fgures 2010. American Cancer Society COMPANY PUBLICATION 2010 August 13
96. Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors. Asaki T, Sugiyama Y, Hamamoto T, Higashioka M, Umehara M, Naito H, Niwa T BIOORG MED CHEM LETT 2006 16 5 1421-1425 (Pubitemid 43143035)
97. CytRx initiates phase 2 clinical trial with bafetinib in advanced prostate cancer. CytRx Corp PRESS RELEASE 2010 September 07
98. Kit polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406). Peter B, Hadzijusufovic E, Blatt K, Gleixner KV, Pickl WF, Thaiwong T, Yuzbasiyan-Gurkan V, Willmann M, Valent P EXP HEMATOL 2010 38 9 782-791
99. Activity of the multi-targeted kinase inhibitor, AT9283, in imatinib-resistant Bcr-Abl positive leukemic cells. Tanaka R, Squires MS, Kimura S, Yokota A, Nagao R, Yamauchi T, Takeuchi M, Yao H, Reule M, Smyth T, Lyons JF et al BLOOD 2010 116 12 2089-2095
100. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, Borthakur G et al BLOOD 2010 116 12 2070-2077
101. Cell death and autophagy induced by INNO-406, a novel Bcr-Abl inhibitor, in philadelphia-positive leukemias. Kamitsuji Y, Adachi S, Kimura S, Watanabe K, Kuroda J, Ashihara E, Maekawa T, Nakahata T EJC SUPPL 2007 5 4 Abs P707
102. FDA approves SPRYCEL (dasatinib) as treatment for adult patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. Bristol-Myers Squibb Co PRESS RELEASE 2010 October 28
103. Long-term effcacy of allogeneic hematopoietic stem cell transplantation (HSCT) in patients (pts) with advanced chronic myeloid leukemia (CML) post imatinib failure. Jabbour E, De Lima M, Silva LD, Giralt S, Cortes J, Qazilbash M, Rondon G, Ciurea S, Jones R, Nieto Y, Korbling M et al BLOOD 2008 112 11 Abs 979
104. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. Loblaw DA, Virgo KS, Nam R, Somerfeld MR, Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott J, Taplin M et al J CLIN ONCOL 2007 25 12 1596-1605 (Pubitemid 46733088)
105. Molecular markers and determinants of prostate cancer metastasis. Gopalkrishnan RV, Kang DC, Fisher PB J CELL PHYSIOL 2001 189 3 245-256 (Pubitemid 33063292)
106. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Yamamoto JF, Goodman MT CANCER CAUSES CONTROL 2008 19 4 379-390
107. Recent advances in therapy for glioblastoma. Clarke J, Butowski N, Chang S ARCH NEUROL 2010 67 3 279-283
108. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: Results of Southwest Oncology Group 9400 study. Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR BLOOD 2008 111 5 2563-2572
109. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ BLOOD 2010 115 2 206-214
110. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confrms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: Results from the International ALL Trial MRC UKALLXII/ECOG2993. Fielding AK, Rowe JM, Richards SM, Buck G, Moorman AV, Durrant IJ, Marks DI, McMillan AK, Litzow MR, Lazarus HM, Foroni L et al BLOOD 2009 113 19 4489-4496
111. Promising outcome of imatinib-combined chemotherapy followed by allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia: Results of the Japan Adult Leukemia Study Group (JALSG) Ph+ALL202 Regimen. Hatta Y, Mizuta S, Ohtake S, Sugiura I, Ueda Y, Kanamori H, Akiyama H, Takeuchi M, Usui N, Yujiri T, Fujieda A et al BLOOD 2009 114 22 Abs 3090
112. Outcome after frontline therapy with the hyper-CVAD and imatinib mesylate regimen for adults with de novo or minimally treated Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL). Thomas DA, Kantarjian HM, Cortes J, Ravandi F, Faderl S, Jones D, Letvak LA, Kebriaei P, Champlin RE, O'Brien S BLOOD 2008 112 11 Abs 2931
113. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Copland M, Hamilton A, Eirick LJ, Baird JW, Allan EK, Jordanides N, Barow M, Mountford JC, Holyoake TL BLOOD 2006 107 11 4532-4539 (Pubitemid 43801382)
114. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, Holyoake TL BLOOD 2002 99 1 319-325
115. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, Arber DA, Slovak ML, Forman SJ BLOOD 2003 101 12 4701-4707 (Pubitemid 36857723)
116. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant Bcr/Abl mutants. Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M, Gambacorti-Passerini C, Boschelli F J CLIN ONCOL 2009 27 3 469-471
117. Primary brain and central nervous system tumors diagnosed in the United States in 2004-2006. Central Brain Tumor Registry of the United States COMPANY PUBLICATION 2010 August 18
118. CytRx begins clinical study of bafetinib for brain cancer. CytRx Corp PRESS RELEASE 2010 November 10
119. Tyrosine kinase inhibitors. Natoli C, Perrucci B, Perrotti F, Falchi L, Iacobelli S CURR CANCER DRUG TARGETS 2010 10 5 462-483
120. Diagnosing and treating chronic lymphocytic leukemia in 2009. Kaufman M, Rubin J, Rai K Oncologyny 2009 23 12 1030-1037
121. Glioblastoma. Miller CR, Perry A ARCH PATHOL LAB MED 2007 131 3 397-406